<![CDATA[Hansa Biopharma — Juni 2024]]>Enig exitnu...Det samtidigt med, at aktien kører under radaren hos mange investorer efter det voldsomme fald i kursen de senere år.

]]>https://dev.proinvestor.com/forum/topic/400751/hansa-biopharma-juni-2024RSS for NodeSat, 06 Jun 2026 04:38:00 GMTSat, 01 Jun 2024 03:03:00 GMT60<![CDATA[Reply to Hansa Biopharma — Juni 2024 on Thu, 27 Jun 2024 12:05:14 GMT]]>Kort video:
Zealand Pharma, Novo, Gubra, Bavarian, ALK , Hansa Biopharma https://proinvestor.com/boards/121107

]]>https://dev.proinvestor.com/forum/post/8007360https://dev.proinvestor.com/forum/post/8007360Thu, 27 Jun 2024 12:05:14 GMT<![CDATA[Reply to Hansa Biopharma — Juni 2024 on Tue, 25 Jun 2024 06:41:27 GMT]]>Godt interview. Mange gode pointer, overvejelser omkring US-dobbeltnotering, bekræfter cash-flow er på plads helt frem til 2026 o.m.a.

]]>https://dev.proinvestor.com/forum/post/8007363https://dev.proinvestor.com/forum/post/8007363Tue, 25 Jun 2024 06:41:27 GMT<![CDATA[Reply to Hansa Biopharma — Juni 2024 on Tue, 25 Jun 2024 06:41:11 GMT]]>Interview med CCO Matthew Shaulis & US President of Hansa Biopharma

https://open.spotify.com/episode/5J46SWex6Zk4Vvv5pVxpmm

(Spotify - The Biohub)

"We're super excited to welcome a phenomenal guest, Matthew Shaulis!
Matthew is the Chief Commercial Officer and US President of Hansa Biopharma. With over 20 years of experience in the pharmaceutical industry, he's held top executive roles at giants like Pfizer and Teva."

]]>https://dev.proinvestor.com/forum/post/8007358https://dev.proinvestor.com/forum/post/8007358Tue, 25 Jun 2024 06:41:11 GMT<![CDATA[Reply to Hansa Biopharma — Juni 2024 on Mon, 24 Jun 2024 03:13:43 GMT]]>Expanded label for Sarepta's DMD therapy Elevidys seen as 'best-case scenario' https://firstwordpharma.com/story/5869033

]]>https://dev.proinvestor.com/forum/post/8007356https://dev.proinvestor.com/forum/post/8007356Mon, 24 Jun 2024 03:13:43 GMT<![CDATA[Reply to Hansa Biopharma — Juni 2024 on Sat, 22 Jun 2024 18:36:21 GMT]]>Så ca 14% af de 3-400 drenge, det vil jo også gi en del salg? har investeret en del i Hansa og tror på om 2-3 år vil det se rigtig godt ud. Men en markeds værdig på 2 mia danske ca pt er jo ingen ting i forhold til hvad de kan omsætte for.

]]>https://dev.proinvestor.com/forum/post/8007355https://dev.proinvestor.com/forum/post/8007355Sat, 22 Jun 2024 18:36:21 GMT<![CDATA[Reply to Hansa Biopharma — Juni 2024 on Sat, 22 Jun 2024 17:41:10 GMT]]>Det spændende er vel også om de så får slået hul på bylden for andre Genterapier 🙂

]]>https://dev.proinvestor.com/forum/post/8007354https://dev.proinvestor.com/forum/post/8007354Sat, 22 Jun 2024 17:41:10 GMT<![CDATA[Reply to Hansa Biopharma — Juni 2024 on Sat, 22 Jun 2024 17:40:37 GMT]]>
  • salg af Imlifidase, hvilket vel svarer til ca. DKK 4mio. pr. solgt behandling. Og så er der milestones
    • ]]>    https://dev.proinvestor.com/forum/post/8007362https://dev.proinvestor.com/forum/post/8007362Sat, 22 Jun 2024 17:40:37 GMT    <![CDATA[Reply to Hansa Biopharma — Juni 2024 on Sat, 22 Jun 2024 17:39:33 GMT]]>Det er ca. 14% af patienter som er potentielle. Ca. 3-400 nyfødte drengebørn i US om året som har DMD. Imlifidase er endnu ikke godkendt i US. Roche står for udrulning af Sareptas genterapi i Europ. Hansa modtager ca 10% i fee,
    hvilket svarer til ca.

    ]]>    https://dev.proinvestor.com/forum/post/8007353https://dev.proinvestor.com/forum/post/8007353Sat, 22 Jun 2024 17:39:33 GMT    <![CDATA[Reply to Hansa Biopharma — Juni 2024 on Sat, 22 Jun 2024 14:39:23 GMT]]>Tak, også det som jeg havde forstået:) så ser vi vel ikke den store stigning på mandag pga Sarepta godkendelse?:)

    ]]>    https://dev.proinvestor.com/forum/post/8007357https://dev.proinvestor.com/forum/post/8007357Sat, 22 Jun 2024 14:39:23 GMT    <![CDATA[Reply to Hansa Biopharma — Juni 2024 on Sat, 22 Jun 2024 09:24:24 GMT]]>De bruger det ikke endnu, du har svaret her: https://clinicaltrials.gov/study/NCT06241950?term=Sarepta&aggFilters=status:act&rank=6&tab=history

    ]]>    https://dev.proinvestor.com/forum/post/8007359https://dev.proinvestor.com/forum/post/8007359Sat, 22 Jun 2024 09:24:24 GMT    <![CDATA[Reply to Hansa Biopharma — Juni 2024 on Sat, 22 Jun 2024 08:36:02 GMT]]>Er det til hver behandling Sarepta bruger
    imlifidase, eller kun en mulighed at bruge?

    ]]>    https://dev.proinvestor.com/forum/post/8007351https://dev.proinvestor.com/forum/post/8007351Sat, 22 Jun 2024 08:36:02 GMT    <![CDATA[Reply to Hansa Biopharma — Juni 2024 on Sat, 22 Jun 2024 06:51:17 GMT]]>Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval In Muscular Dystrophy

    https://www.investors.com/news/technology/sarepta-stock-expanded-approval-elevidys-duchenne-muscular-dystrophy-gene-therapy/

    "The approval expands the market for Elevidys by more than tenfold, Leerink Partners analyst Joseph Schwartz said. Under the original approval, about 7% of patients were eligible for the gene therapy. Now, about 80% are eligible, he said in a report."

    ]]>    https://dev.proinvestor.com/forum/post/8007349https://dev.proinvestor.com/forum/post/8007349Sat, 22 Jun 2024 06:51:17 GMT    <![CDATA[Reply to Hansa Biopharma — Juni 2024 on Fri, 21 Jun 2024 12:13:43 GMT]]>Kursudviklingen for Sarepta Therapeutics er ganske pæn i US i dag fredag 🙂

    ]]>    https://dev.proinvestor.com/forum/post/8007350https://dev.proinvestor.com/forum/post/8007350Fri, 21 Jun 2024 12:13:43 GMT    <![CDATA[Reply to Hansa Biopharma — Juni 2024 on Fri, 21 Jun 2024 08:00:39 GMT]]>Sarepta's DMD gene therapy secures much-sought-after label expansion https://firstwordpharma.com/story/5868924

    ]]>    https://dev.proinvestor.com/forum/post/8007348https://dev.proinvestor.com/forum/post/8007348Fri, 21 Jun 2024 08:00:39 GMT    <![CDATA[Reply to Hansa Biopharma — Juni 2024 on Fri, 21 Jun 2024 05:17:53 GMT]]>Det bliver spændende. 🙂

    ]]>    https://dev.proinvestor.com/forum/post/8007352https://dev.proinvestor.com/forum/post/8007352Fri, 21 Jun 2024 05:17:53 GMT    <![CDATA[Reply to Hansa Biopharma — Juni 2024 on Fri, 21 Jun 2024 04:52:52 GMT]]>... vi må se på mandag, hvordan det går 🙂

    ]]>    https://dev.proinvestor.com/forum/post/8007346https://dev.proinvestor.com/forum/post/8007346Fri, 21 Jun 2024 04:52:52 GMT    <![CDATA[Reply to Hansa Biopharma — Juni 2024 on Fri, 21 Jun 2024 04:22:19 GMT]]>Sarepta Therapeutics surges 36% after-hours following expanded FDA approval

    https://www.investing.com/news/stock-market-news/sarepta-therapeutics-surges-36-afterhours-following-expanded-fda-approval-3491190

    ]]>    https://dev.proinvestor.com/forum/post/8007344https://dev.proinvestor.com/forum/post/8007344Fri, 21 Jun 2024 04:22:19 GMT    <![CDATA[Reply to Hansa Biopharma — Juni 2024 on Fri, 21 Jun 2024 04:21:59 GMT]]>Kursudviklingen for Sarepta Therapeutics efter børstid kommer ikke til at blive afspejlet direkte, da DMD-aftalen kun udgør en mindre del/værdi af Hansa Biopharmas portefølje, som eksempelvis nævnt i en tidligere analyse fra Penser Access (nu overtaget af Carnegie).

    ]]>    https://dev.proinvestor.com/forum/post/8007361https://dev.proinvestor.com/forum/post/8007361Fri, 21 Jun 2024 04:21:59 GMT    <![CDATA[Reply to Hansa Biopharma — Juni 2024 on Fri, 21 Jun 2024 04:21:52 GMT]]>Mange tak til ALLE.

    ]]>    https://dev.proinvestor.com/forum/post/8007343https://dev.proinvestor.com/forum/post/8007343Fri, 21 Jun 2024 04:21:52 GMT    <![CDATA[Reply to Hansa Biopharma — Juni 2024 on Fri, 21 Jun 2024 04:04:21 GMT]]>@exitnu. Tak for alle dine indlæg gennem tiden. I dag med
    et af de absolut bedste 🙂

    ]]>    https://dev.proinvestor.com/forum/post/8007340https://dev.proinvestor.com/forum/post/8007340Fri, 21 Jun 2024 04:04:21 GMT    <![CDATA[Reply to Hansa Biopharma — Juni 2024 on Fri, 21 Jun 2024 03:33:03 GMT]]>God morgen 🙂

    ]]>    https://dev.proinvestor.com/forum/post/8007347https://dev.proinvestor.com/forum/post/8007347Fri, 21 Jun 2024 03:33:03 GMT    <![CDATA[Reply to Hansa Biopharma — Juni 2024 on Fri, 21 Jun 2024 03:23:32 GMT]]>Godmorgen 🙂 super nyhed exitnu

    ]]>    https://dev.proinvestor.com/forum/post/8007339https://dev.proinvestor.com/forum/post/8007339Fri, 21 Jun 2024 03:23:32 GMT    <![CDATA[Reply to Hansa Biopharma — Juni 2024 on Fri, 21 Jun 2024 01:57:06 GMT]]>Godmorgen 🙂

    ]]>    https://dev.proinvestor.com/forum/post/8007341https://dev.proinvestor.com/forum/post/8007341Fri, 21 Jun 2024 01:57:06 GMT    <![CDATA[Reply to Hansa Biopharma — Juni 2024 on Thu, 20 Jun 2024 19:47:01 GMT]]>– FDA grants traditional approval to ELEVIDYS for ambulatory Duchenne patients

    – FDA grants accelerated approval to ELEVIDYS for non-ambulatory Duchenne patients

    – Sarepta will host an investor conference call on June 21, 2024, at 8:30 a.m. ET

    ]]>    https://dev.proinvestor.com/forum/post/8007336https://dev.proinvestor.com/forum/post/8007336Thu, 20 Jun 2024 19:47:01 GMT